JP2019516352A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516352A5
JP2019516352A5 JP2018551409A JP2018551409A JP2019516352A5 JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5 JP 2018551409 A JP2018551409 A JP 2018551409A JP 2018551409 A JP2018551409 A JP 2018551409A JP 2019516352 A5 JP2019516352 A5 JP 2019516352A5
Authority
JP
Japan
Prior art keywords
clone
seq
amino acid
receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018551409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019516352A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025613 external-priority patent/WO2017173410A1/en
Publication of JP2019516352A publication Critical patent/JP2019516352A/ja
Publication of JP2019516352A5 publication Critical patent/JP2019516352A5/ja
Priority to JP2022035975A priority Critical patent/JP7561155B2/ja
Priority to JP2024070373A priority patent/JP2024105337A/ja
Pending legal-status Critical Current

Links

JP2018551409A 2016-04-01 2017-03-31 Flt3に対するキメラ受容体及びその使用方法 Pending JP2019516352A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022035975A JP7561155B2 (ja) 2016-04-01 2022-03-09 Flt3に対するキメラ受容体及びその使用方法
JP2024070373A JP2024105337A (ja) 2016-04-01 2024-04-24 Flt3に対するキメラ受容体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317219P 2016-04-01 2016-04-01
US62/317,219 2016-04-01
PCT/US2017/025613 WO2017173410A1 (en) 2016-04-01 2017-03-31 Chimeric receptors to flt3 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022035975A Division JP7561155B2 (ja) 2016-04-01 2022-03-09 Flt3に対するキメラ受容体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2019516352A JP2019516352A (ja) 2019-06-20
JP2019516352A5 true JP2019516352A5 (show.php) 2020-05-07

Family

ID=58530714

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018551409A Pending JP2019516352A (ja) 2016-04-01 2017-03-31 Flt3に対するキメラ受容体及びその使用方法
JP2022035975A Active JP7561155B2 (ja) 2016-04-01 2022-03-09 Flt3に対するキメラ受容体及びその使用方法
JP2024070373A Pending JP2024105337A (ja) 2016-04-01 2024-04-24 Flt3に対するキメラ受容体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022035975A Active JP7561155B2 (ja) 2016-04-01 2022-03-09 Flt3に対するキメラ受容体及びその使用方法
JP2024070373A Pending JP2024105337A (ja) 2016-04-01 2024-04-24 Flt3に対するキメラ受容体及びその使用方法

Country Status (26)

Country Link
US (2) US20190183931A1 (show.php)
EP (1) EP3436479A1 (show.php)
JP (3) JP2019516352A (show.php)
KR (2) KR102389096B1 (show.php)
CN (1) CN109641956A (show.php)
AR (2) AR109626A1 (show.php)
AU (3) AU2017240801A1 (show.php)
BR (1) BR112018070187A8 (show.php)
CA (1) CA3019655A1 (show.php)
CL (1) CL2018002792A1 (show.php)
CO (1) CO2018011804A2 (show.php)
CR (2) CR20180518A (show.php)
EA (1) EA201892193A1 (show.php)
IL (2) IL296966A (show.php)
MA (1) MA44507A (show.php)
MX (1) MX2023013729A (show.php)
MY (2) MY201207A (show.php)
NZ (1) NZ746925A (show.php)
PE (2) PE20241061A1 (show.php)
PH (1) PH12018502118B1 (show.php)
SA (1) SA518400154B1 (show.php)
SG (2) SG10201911963VA (show.php)
TN (1) TN2018000337A1 (show.php)
TW (2) TW202313669A (show.php)
UA (1) UA128326C2 (show.php)
WO (1) WO2017173410A1 (show.php)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
US10913716B2 (en) 2016-03-31 2021-02-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
KR102397674B1 (ko) 2016-04-01 2022-05-18 카이트 파마 인코포레이티드 Bcma 결합 분자 및 그의 사용 방법
CR20180494A (es) 2016-04-01 2019-01-29 Janssen Pharmaceuticals Inc Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA128781C2 (uk) 2016-04-01 2024-10-23 Кайт Фарма, Інк. Т-клітина, спосіб її отримання та застосування
SG11201808411RA (en) * 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA039702B1 (ru) 2017-05-22 2022-03-01 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
CN119899277A (zh) 2017-06-02 2025-04-29 辉瑞公司 靶向flt3的嵌合抗原受体
ES2975221T3 (es) 2017-08-03 2024-07-04 Amgen Inc Muteínas de interleucina-21 y métodos de tratamiento
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
JOP20200172A1 (ar) 2018-01-12 2020-07-12 Amgen Inc الأجسام المضادة لـ pd-1 وطرق العلاج
SG11202010454PA (en) * 2018-03-23 2020-11-27 Gavish Galilee Bio Appl Ltd Genetically reprogrammed tregs expressing membrane-bound il-10
JP7479290B2 (ja) * 2018-04-10 2024-05-08 アムジエン・インコーポレーテツド Dll3に対するキメラ受容体及びその使用方法
EP3774907A1 (en) 2018-04-13 2021-02-17 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
SG11202104352XA (en) 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
EP3952886A1 (en) * 2019-04-10 2022-02-16 Elevatebio Technologies, Inc Flt3-specific chimeric antigen receptors and methods of using the same
AU2020265679A1 (en) 2019-04-30 2021-12-23 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CA3161103A1 (en) * 2019-12-16 2021-06-24 Carl Deselm Chimeric antigen receptor dendritic cells (car-dcs) and methods of making and using same
AU2021256053A1 (en) * 2020-04-17 2022-11-10 City Of Hope FLT3-targeted chimeric antigen receptor modified cells for treatment of FLT3-positive malignancies
CN111808821B (zh) * 2020-06-24 2022-06-14 南方医科大学珠江医院 Flt3-nkg2d双靶点car-t的构建与制备
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
AU2022212090A1 (en) * 2021-01-28 2023-07-06 Allogene Therapeutics, Inc. Methods for transducing immune cells
AU2022212130A1 (en) 2021-01-29 2023-07-06 Allogene Therapeutics, Inc. KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
CN116410315A (zh) * 2021-12-31 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型靶向人flt3的嵌合抗原受体修饰的t细胞的构建及应用
CA3261440A1 (en) 2022-07-29 2024-02-01 Allogene Therapeutics, Inc. MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
CN120157768A (zh) * 2023-12-15 2025-06-17 博生吉安科细胞技术有限公司 一种识别flt3-car分子的单克隆抗体及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
CA2406864A1 (en) 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
TWI615407B (zh) * 2005-08-26 2018-02-21 羅齊克雷雅公司 具有經改變細胞傳訊活性之改質抗原結合分子
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
EP2516468B1 (en) * 2009-12-23 2016-03-02 Synimmune GmbH Anti-flt3 antibodies and methods of using the same
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9845362B2 (en) * 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9024028B2 (en) 2011-01-26 2015-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for the synthesis of multimerizing agents
JP6203705B2 (ja) 2011-03-23 2017-09-27 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための方法および組成物
EP3421489B1 (en) * 2012-03-23 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
SI3613439T1 (sl) 2013-02-15 2021-11-30 The Regents Of The University Of California Himerni antigenski receptor in postopki njegove uporabe
JP6541639B2 (ja) 2013-03-14 2019-07-10 ベリカム ファーマシューティカルズ, インコーポレイテッド T細胞増殖をコントロールするための方法
AU2014296626B2 (en) 2013-07-29 2019-03-07 Regeneron Pharmaceuticals, Inc. Multipartite signaling proteins and uses thereof
EP4420663A3 (en) 2013-12-20 2024-10-30 Novartis AG Regulatable chimeric antigen receptor
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症
MX377344B (es) * 2014-07-31 2025-03-07 Amgen Res Munich Gmbh Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
BR112017005631A2 (pt) * 2014-09-19 2018-06-26 City Of Hope células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
SG11201808411RA (en) * 2016-04-01 2018-10-30 Kite Pharma Inc Chimeric antigen and t cell receptors and methods of use

Similar Documents

Publication Publication Date Title
JP2019516352A5 (show.php)
HRP20221348T1 (hr) Kimerni receptori i postupci njihove uporabe
JP2019515661A5 (show.php)
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
JP2017524367A5 (show.php)
JP2017522879A5 (show.php)
JP2021000103A5 (show.php)
RU2017105160A (ru) Лечение рака с помощью химерного антигенного рецептора к cd33
JPWO2019200007A5 (show.php)
RU2017105065A (ru) Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
RU2017105161A (ru) Лечение рака с использованием химерного антигенного рецептора cll-1
IL277398B1 (en) Pd-l1 binding affimers, and uses related thereto
JP2019523301A5 (show.php)
JPWO2020180591A5 (show.php)
JP2020513839A5 (show.php)
JP2019525771A5 (show.php)
JP2019516350A5 (show.php)
JP2018538339A5 (show.php)
CA3032054A1 (en) Combination therapies of chimeric antigen receptors and pd-1 inhibitors
JP2019513370A5 (show.php)
RU2017108903A (ru) Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
RU2019128921A (ru) Антитело к il-13ra2 и его применение
EP4281566A1 (en) Methods for high throughput screening of chimeric antigen receptors
US20250000976A1 (en) Anti-bcma single domain antibodies and therapeutic constructs
JP2020500903A5 (show.php)